Cytiva, a Danaher company and a global leader in the life sciences industry, and WhiteLab Genomics, a techbio company specializing in artificial intelligence for genomic medicine research and development, announced a collaboration to accelerate the development of next-generation genomic medicines.

Cytiva，丹纳赫集团旗下公司，生命科学行业的全球领导者，与专注于基因组医学研发的人工智能技术生物公司 WhiteLab Genomics 宣布合作，以加速下一代基因组药物的开发。

As part of this collaboration, WhiteLab Genomics will use its proprietary AI-powered technology to optimize and accelerate stable cell line development. By analyzing complex biological data with advanced data analysis, WhiteLab’s platform will help improve the stable cell line clone selection process, all through computer simulations..

作为此次合作的一部分，WhiteLab Genomics将使用其专有的AI技术支持技术来优化和加速稳定细胞系的开发。通过利用先进的数据分析处理复杂的生物数据，WhiteLab的平台将帮助改进稳定细胞系克隆选择过程，且全程通过计算机模拟完成。

“Through the integration of AI-driven predictive modeling into AAV development workflows, we aim to reduce development timelines and associated costs by up to 70%,” said David Del Bourgo, CEO and Co-Founder of WhiteLab Genomics. “This is a significant impact when the total cost of bringing a genomic medicine to market can approach nearly USD 2 billion, enabling a more efficient, scalable path to clinical and commercial readiness in genomic medicine.”.

“通过将人工智能驱动的预测建模整合到AAV开发工作流程中，我们旨在将开发时间线和相关成本减少多达70%，”WhiteLab Genomics首席执行官兼联合创始人David Del Bourgo表示。“当将一种基因组药物推向市场的总成本接近近20亿美元时，这一影响意义重大，能够为基因组医学提供一条更高效、可扩展的临床和商业化路径。”

Combined with Cytiva’s expertise in stable cell lines for AAV production, the collaboration aims to benefit researchers in advanced therapies and their patients.

结合Cytiva在AAV生产用稳定细胞系方面的专业知识，此次合作旨在使先进疗法的研究人员及其患者受益。

“Genomic medicines will be critical to address some of the world’s greatest health challenges. By combining Cytiva’s experience with WhiteLab’s technology, we intend to help manufacturers reach clinical and regulatory milestones faster benefiting patients around the world,” said Emmanuel Abate, President of Genomic Medicine, Cytiva.

“基因组药物将对解决世界上一些最大的健康挑战至关重要。通过结合Cytiva的经验与WhiteLab的技术，我们旨在帮助制造商更快地达成临床和监管里程碑，造福全球患者，”Cytiva基因组药物总裁Emmanuel Abate表示。

Learn more about optimizing your cell line strategy for better viral vector production at https://cytiva.link/BPI-CLD-Strategy.

欲了解有关优化细胞系策略以提高病毒载体生产的更多信息，请访问 https://cytiva.link/BPI-CLD-Strategy。

Cytiva and the drop logo are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Cytiva 和水滴形标志是 Global Life Sciences Solutions USA LLC 或其以 Cytiva 名义开展业务的关联公司的商标。

About WhiteLab Genomics

关于WhiteLab基因组学

WhiteLab Genomics, a pioneer in the accelerated development of genomic medicines, sits at the intersection of artificial intelligence and biology. Founded in 2019 and supported by Y-Combinator, the company is establishing itself as a key player in genomic medicine innovation. Its proprietary AI technology enables the analysis of complex biological data and the in silico design of optimized therapeutic candidates, thus reducing development time, costs, and associated risks.

WhiteLab Genomics是一家致力于加速基因组药物开发的先锋企业，处于人工智能与生物学的交汇点。公司成立于2019年，并得到Y-Combinator的支持，现已成为基因组医学创新领域的重要参与者。其专有的人工智能技术能够分析复杂的生物数据，并在计算机上设计优化的治疗候选方案，从而缩短开发时间、降低成本以及相关风险。

WhiteLab collaborates with major pharmaceutical companies (such as Sanofi), leading academic institutions, and innovative biotech companies. WhiteLab is a member of the prestigious French Tech 2030 program and recently joined Bayer Co.Lab in Cambridge (USA) as well as the Technology Network of Ginkgo Bioworks.

WhiteLab与主要制药公司（如赛诺菲）、领先的学术机构和创新生物技术公司合作。WhiteLab是享有盛誉的法国Tech 2030计划的成员，最近还加入了位于美国剑桥的拜耳Co.Lab以及Ginkgo Bioworks的技术网络。

Learn more at White Lab Genomics..

请访问白实验室基因组学了解更多信息。

About Cytiva

关于Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers.

在Cytiva，我们的使命是推动和加速治疗药物的开发。我们在40多个国家拥有15,000名员工，致力于利用我们的专业知识和才能，为客户提供更高的灵活性、产能和效率。我们广泛而深入的工具与技术组合、全球规模以及一流的服务，为从发现到交付的各个环节提供了关键支持，客户涵盖研究人员、新兴生物技术公司、大规模生物制药企业以及合同制造商。

Learn more at Cytiva.com.

请访问Cytiva.com了解更多信息。

Cytiva is proud to be part of Danaher. Visit www.Danaher.com to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health.

Cytiva 很自豪能成为丹纳赫的一部分。访问 www.Danaher.com 了解更多关于丹纳赫的信息，这是一家领先的生命科学和诊断创新公司，致力于加速科学和技术的力量以改善人类健康。

Media contact:

媒体联系人：

Media Contact:

媒体联系人：

Colleen Connolly

科琳·康诺利

Colleen.Connolly@cytiva.com

科琳·康诺利@cytiva.com

WhiteLab Genomics

白实验室基因组学

press@whitelabgx.com

press@whitelabgx.com

Source: cytivalifesciences.com

来源：cytivalifesciences.com